News >

Rovalpituzumab Tesirine Active and Safe in Small Cell Lung Cancer

Allie Strickler @Alliejayes
Published: Monday, Feb 13, 2017

Dr. Charles M. Rudin

Charles M. Rudin, MD, PhD

Rovalpituzumab tesirine (Rova-T), a DLL3-targeted antibody-drug conjugate, demonstrated encouraging single-agent antitumor activity with a manageable safety profile in the treatment of patients with recurrent small cell lung cancer (SCLC), according to the results of a phase I study published in The Lancet Oncology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication